Clinical Trials Logo

Somatic Mutation clinical trials

View clinical trials related to Somatic Mutation.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06357845 Not yet recruiting - Somatic Mutation Clinical Trials

Linking Somatic Mutation Rate With Baseline Exposure in East Palestine

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to This research team is conducting this study to develop methods to measure the biological impact of exposure to the chemicals released following the February 3, 2023 train derailment on residents of East Palestine, Ohio, and surrounding communities. The main question it aims to answer is: - What biological impact will be measured based on DNA damage? - In participants who provide a biospecimen, how are biomarker changes related to proximity to the derailment and variations in residents' health histories and behaviors? Participants will: - Complete a brief survey asking about experiences related to the February 3, 2023 train derailment, health experiences, and concerns following the derailment, and background information regarding health history. - Possibly contribute biospecimens such as blood, spit, hair, and/or toenail clippings. - Receive communication about study updates and future research opportunities. - A total of 40 study participants will be recruited to participate in a 90-minute interview. The interviews will be video and audio recorded.

NCT ID: NCT04788927 Not yet recruiting - Clinical trials for Head and Neck Cancer

Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study

PPGL-Pred
Start date: October 1, 2023
Phase:
Study type: Observational

Phaeochromocytomas and paragangliomas (PPGLs) are tumours of the adrenal medulla and extra-adrenal sympathetic nervous system, some which can become metastatic. It is a very rare disease and the tumours are often detected late. Approximately 50 % of the tumours are caused by germline genetic variants screening programmes are recommended for patients and their family members; however, they are not yet well-targeted with respect to individual prognosis. In this study the investigatorscaim to characterize the genotype-phenotype associations in all Danish patients (n=400) diagnosed with PPGLs who have been followed in tertiary centres using medical records and national registries. To this end novel immunohistochemical, genetic, and epigenetic biomarkers in tumour tissues samples from biobank material (blood samples and tumour tissue) will be investigated to develop a comprehensive predictive algorithm for disease prognosis. The study will provide a clinical tool for an improved targeted screening program and subsequently prevention of disease development.